Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.

Xinan Sheng,Jie Jin,Zhisong He,Yiran Huang,Ai-Ping Zhou,Jinwan Wang,Xiubao Ren,Dingwei Ye,Xu Zhang,Shukui Qin,Fangjian Zhou,Yanfang Guo,Jun Guo

Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.

2018

Xinan Sheng
Jie Jin
Zhisong He
Yiran Huang
Ai-Ping Zhou
Jinwan Wang
Xiubao Ren
Dingwei Ye
Xu Zhang
Shukui Qin
Fangjian Zhou
Yanfang Guo
Jun Guo

e16588Background: A pooled analysis of treatment-naive Chinese pts enrolled in the phase 3 COMPARZ studies VEG108844 (randomized, open-label, global study) and VEG113078 (sub-study to VEG108844 con...

Keywords:

Subgroup analysis
Pathology
Pazopanib
Cancer research
Renal cell carcinoma
Sunitinib
Medicine
pooled analysis
Oncology
in patient
Internal medicine
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations